Trial Profile
Basiliximab +/- antithymocyte globulin as induction therapy for the prevention of rejection in recipients of deceased donor kidneys
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Sep 2013
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Basiliximab (Primary) ; Mycophenolate mofetil; Steroids; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 11 Sep 2013 Results presented at the 16th Congress of the European Society for Organ Transplantation.
- 23 Aug 2013 New trial record